1 August 2024 - Medison Pharma, alongside their partner Alnylam Pharmaceuticals, are pleased to announce that from 1 August 2024, Onpattro (patisiran) is listed on the PBS for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients, with stage 1 or stage 2 polyneuropathy, confirmed by genetic testing.

Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis also referred to as ATTRv) is a rare, rapidly progressing and fatal type of amyloidosis that runs in families and occurs when certain genetic mutations are inherited.

Read Medison Pharma press release